
FORM D

Notice of Exempt Offering of Securities

## **UNITED STATES SECURITIES** AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity	
CIK (Filer ID Number) Previous Name(s)	None Entity Type
0001567264 Intensity Therapeutic	s, Corporation
Name of Issuer	C Limited Partnership
Intensity Therapeutics, Inc.	C Limited Liability Company
Jurisdiction of Incorporation/Organization	C General Partnership
DELAWARE	O Business Trust
Year of Incorporation/Organization	C Other
C Over Five Years Ago	
Within Last Five Years     (Specify Year)	

- Yet to Be Formed

# 2. Principal Place of Business and Contact Information

Name of Issuer Intensity Therapeutics, Inc.			
Street Address 1		Street Address 2	
8 Wright Street		Suite 107	
City	State/Province/Countr	y ZIP/Postal Code	Phone No. of Issuer
Westport	CONNECTICUT	06880	203-682-2434

# 3. Related Persons

Last Name		First Name			Middle	Name	
Bender		Lewis			H.		
Street Address 1			S	treet Address 2			
8 Wright Street, Suite	107						
City		State/Province/O	Count	ry	ZIP/Pos	stal Code	
Westport		CONNECTIC	UT		06880		
Relationship:	Execut	tive Officer	•	Director		Promoter	
Last Name		First Name			Middle	Name	]
Walters, M.D.		Ian			B.		
Street Address 1			S	treet Address 2			
8 Wright Street, Suite	107						
City		State/Province/O	Count	ry	ZIP/Pos	stal Code	
Westport		CONNECTIC	UT		06880	)	
Relationship:	Execu	tive Officer		Director		Promoter Promoter	

Clarification of Response (if No	ecessary)
----------------------------------	-----------

Last Name	First Name		Middle Name	
Cooke	Robert			
Street Address 1		Street Addre	ess 2	
8 Wright Street, Suite 1	07			
City	State/Provin	ice/Country	ZIP/Postal Code	
Westport	CONNEC	TICUT	06880	
	T T C C C C	Director		
Relationship:	Executive Officer	Director	Promoter	

## 4. Industry Group

- C Agriculture
  - **Banking & Financial Services**
  - C Commercial Banking
  - C Insurance
  - C Investing
  - C Investment Banking
  - C Pooled Investment Fund
  - Other Banking & Financial C Services

### C Business Services

## Energy

- C Coal Mining C Electric Utilities
- C Energy Conservation C Environmental Services
- C Oil & Gas
- C Other Energy

5. Issuer Size **Revenue Range** 

C

C

C

C

C

C

œ

C

- C Biotechnology Health Insurance
- C 0 Hospitals & Physicians

Health Care

- Pharmaceuticals  $\odot$
- C Other Health Care

## C Manufacturing

- Real Estate
  - C Commercial
  - 0 Construction
  - **REITS & Finance** 0
  - C Residential

0

C

C Other Real Estate

## C Retailing

- C Restaurants
  - Technology
  - C Computers

  - **C** Telecommunications
  - C Other Technology

### Travel

- C Airlines & Airports
- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel
- O Other

No Revenues

\$1 - \$1,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

Over \$100,000,000

Decline to Disclose

Not Applicable

\$25,000,001 - \$100,000,000

## Aggregate Net Asset Value Range

- No Aggregate Net Asset Value
- 0 \$1 - \$5,000,000
  - \$5,000,001 \$25,000,000
- 0 \$25,000,001 - \$50,000,000
- C \$50,000,001 - \$100,000,000
- C Over \$100,000,000
- C Decline to Disclose
- 0 Not Applicable

#### 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) Rule 505 Г or (iii))

Rule 504 (b)(1)(i)	Rule 506(b)
Rule 504 (b)(1)(ii)	Rule 506(c)
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	Investment Company Act Section 3(c)
1	

7.	Type of F	iling		
Π	New Notice	Date of First Sale	2013-01-05	First Sale Yet to Occur
•	Amendment			

• Yes C No

# 8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

9.	Type(s) of Securitie	es (	Offered (select all that apply)
Г	Pooled Investment Fund Interests	•	Equity
Г	Tenant-in-Common Securities	•	Debt
	Mineral Property Securities	•	Option, Warrant or Other Right to Acquire Another Security
•	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

# 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? C Yes  $\circ$  No

Clarification of Response (if Necessary)

11. Minimum Investment		
Minimum investment accepted from any outside investor	\$ 0	USD

12. Sales Compensation	
Recipient	Recipient CRD Number 🔲 None
Cato Capital, LLC	133142
(Associated) Broker or Dealer V None	(Associated) Broker or Dealer CRD None
Street Address 1	Street Address 2
31 Woodland Street, 11th Floor	
City Stat	e/Province/Country ZIP/Postal Code
Hartford	DNNECTICUT 06105
State(s) of Solicitation 🔲 All States 🔲 Fo	oreign/Non-US

CALIFORNIA
CONNECTICUT
MARYLAND
MASSACHUSETTS
NEW JERSEY
NEW YORK
NORTH CAROLINA
TEXAS

13. Offering and Sales Amounts
Total Offering Amount 💲 USD 🔽 Indefinite
Total Amount Sold \$ 1750000 USD
Total Remaining to be \$ USD III Indefinite
Clarification of Response (if Necessary)
Offering of convertible notes, common stock, and warrants to purchase common stock (including underlying shares to be issued
upon conversion of notes or exercise of warrants).
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors, who already have invested in the
offering
Regardless of whether securities in the offering have been or may be sold to percent who do not explicitly as georedited investors, onter the total
to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 40000 USD Estimate
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 40000 USD For Estimate Finders' Fees \$ 0 Estimate
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 40000 USD For Estimate Finders' Fees \$ 0 Estimate
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 40000 USD For Estimate Finders' Fees \$ 0 Estimate
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount. Sales Commissions \$ 40000 USD For Estimate Finders' Fees \$ 0 Estimate
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.  Sales Commissions \$ 40000 USD Estimate Finders' Fees \$ 0 USD Estimate Clarification of Response (if Necessary)  16. Use of Proceeds
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.  Sales Commissions \$ 40000 USD Estimate Finders' Fees \$ 0 Estimate Clarification of Response (if Necessary)
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.  Sales Commissions \$ 40000 USD E Estimate Finders' Fees \$ 0 USD E Estimate Clarification of Response (if Necessary)  16. Use of Proceeds Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.  Sales Commissions \$ 40000 USD F Estimate Finders' Fees \$ 0 USD Estimate Clarification of Response (if Necessary) <b>16. Use of Proceeds</b> Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the state is principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains its principal place of business or any State in which the state in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal place of business or any State in which the issuer maintains is principal pl
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Intensity Therapeutics, Inc.	/s/ Lewis H. Bender	Lewis H. Bender	President, Treasurer and Secretary	2014-11-24